Objective:
To evaluate the retinal safety signals associated with GLP-1 receptor agonists in patients with diabetes and ocular risk factors.
Key Findings:
- Increased risk of diabetic retinopathy complications with rapid HbA1c reduction.
- Conflicting evidence on GLP-1's impact on age-related macular degeneration.
- Potential increased risk of NAION with semaglutide, but inconsistent findings in larger studies.
- No increased risk of retinal vein occlusion associated with GLP-1 use.
Interpretation:
Current evidence does not warrant withholding GLP-1 therapy due to ocular safety concerns, but close monitoring is advised for at-risk patients.
Limitations:
- Conflicting study results on AMD and NAION may stem from design limitations.
- Inconsistent findings across different studies regarding NAION risk.
Conclusion:
Baseline retinal examinations are recommended before initiating GLP-1 therapy, especially for patients with preexisting retinopathy or severe ocular risk factors.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.